Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19237285 | 0.74 | SLC6A4 (0.54) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL8970530 | 0.73 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 | |
| Hydrochloric Acid SCHEMBL8559271 | 0.72 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL13543992 | 0.72 | DRD2 (0.53) | CYP3A4 | |
| SCHEMBL4683352 | 0.70 | SIGMAR1 (0.47) | — | |
| SCHEMBL11535461 | 0.70 | OPRM1 (0.46) | — | |
| SCHEMBL7134955 | 0.69 | SLC6A4 (0.66) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL7134948 | 0.69 | SLC6A4 (0.66) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL27999604 | 0.68 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6957461 | 0.68 | SLC6A4 (0.70) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569933-B1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060058284-A1 | Pyrrolidine and azetidine compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
| EP-1569933-A1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SmithKline Beecham Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004055016-A1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058284-A1 | Pyrrolidine and azetidine compounds as ccr5 antagonists | CCR5, CCL5, CXCR1 | SLC6A2 1823/4885SLC6A4 1492/4885SLC6A3 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.